ºñ½ºÅ×·ÎÀ̵å¼Ò¿°Á¦ °ü·Ã ¼Òȼº ±Ë¾çÀÇ ÃÖ½ÅÁö°ß
Update on NSAIDs Related Peptic Ulcers
´ëÇѳ»°úÇÐȸÁö 2014³â 86±Ç 6È£ p.664 ~ p.672
ÃÖµ¿¿í(Choi Dong-Wook) - °¿ø´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
¹Ú¼ºÃ¶(Park Sung-Chul) - °¿ø´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
ÀüÈÆÀç(Chun Hoon-Jai) - °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic, antipyretic, and anti-inflammatory properties and are widely used for treating musculoskeletal and cardiovascular diseases. Notwithstanding these therapeutic efficacies, gastrointestinal toxicity is the major health problem associated with NSAID use. NSAID-related peptic ulcers are a well-known complication due to direct mucosal injury and cyclooxygenase inhibition. Risk factors for NSAID-related peptic ulcers include a prior history of peptic ulcer; age > 65 years; high-dose NSAID therapy; and concurrent use of aspirin (including low dose), corticosteroids, or anticoagulants. In addition, Helicobacter pylori infection is an independent risk factor; therefore, eradication therapy is recommended in high-risk patients using NSAIDs. Currently, misoprostol, H2-receptor antagonists, proton pump inhibitors, and COX-2 selective inhibitors are used to prevent and treat NSAID-related peptic ulcers. Further, strategic approaches are required through appropriate NSAID use and risk factor stratification to prevent NSAID-related peptic ulcers and associated complications.
Å°¿öµå
Non-steroidal anti-inflammatory drugs, Peptic ulcer, Treatment, Prevention
KMID :
0882420140860060664
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)